VERVE-102 – Talk Bio

Eli Lilly Pays $1B Upfront to Acquire Verve Therapeutics, Expanding Cardiovascular Gene Editing Portfolio

2 weeks ago talkbio0Tagged Acquisition, Cardiovascular Diseases, eli lilly, Gene Modification, Heart Diseases, PCSK9 protein, human, VERVE-102

Eli Lilly; Verve Therapeutics; gene editing; cardiovascular disease; acquisition; PCSK9; VERVE-102; biotech; heart disease

Verve’s 2nd swing at PCSK9 editing yields clean safety profile, teeing up Lilly opt-in decision

3 months ago talkbio0Tagged Safety, VERVE-102

VERVE-102, Safety

Verve Temporarily Halts Lead Base Editing Study Following Adverse Event, Prioritizes Alternative Therapy

1 year ago talkbio0Tagged Adverse event, Alanine Transaminase, Alternative Therapies, Cognitive function: initiation, Elevation procedure, Grade three rank, Heart-1 study, Heart-2 clinical trial, Ionizable, Lead base editing program, lipid delivery system, Pause enrollment, Phase Ib Heart-2 clinical trial, Q2 2024, SAEs, Serious adverse events, Thrombocytopenia, VERVE-101, VERVE-102

Verve Therapeutics, Lead base editing program, Adverse event, VERVE-101, Serious adverse events (SAEs), Grade 3 ALT elevation, Thrombocytopenia, Pause enrollment in Heart-1 study, Alternative therapy focus: VERVE-102, Ionizable lipid delivery system, Phase Ib Heart-2 clinical trial, Q2 2024 initiation of Heart-2 clinical trial.